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Background: Therapeutic reference pricing (TRP) based on the WHO daily defined dose (DDD) is a method
frequently employed for the cost-containment of pharmaceuticals. Our objective was to compare average drug
use in the real world with DDD and to evaluate whether TRP based on DDD could result in cost savings on
maintenance medication and the total direct health expenditures for asthma patients treated with Symbicort
Turbuhaler (SYT) and Seretide Diskus (SED) in Hungary.
Methods: Real-world data were derived from the Hungarian National Health Insurance Fund database. Average
doses and costs were compared between the high-dose and medium-dose SYT and SED groups. Multiple linear
regressions were employed to adjust the data for differences in the gender and age distribution of patients.
Results: 27,779 patients with asthma were included in the analysis. Average drug use was lower than DDD in all
groups, 1.38-1.95 inhalations in both SED groups, 1.28-1.97 and 1.74-2.49 inhalations in the medium and high-dose
SYT groups, respectively. Although the cost of SED based on the DDD would be much lower than the cost of SYT
in the medium-dose groups, no difference was found in the actual cost of the maintenance therapy. No significant
differences were found between the groups in terms of total medical costs.
Conclusions: Cost-containment initiatives by payers may influence clinical decisions. TRP for inhalation asthma
drugs raises special concern, because of differences in the therapeutic profile of pharmaceuticals and the lack of
proven financial benefits after exclusion of the effect of generic price erosion. Our findings indicate that the
presented TRP approach of asthma medications based on the daily therapeutic costs according to the WHO DDD
does not result in reduced public healthcare spending in Hungary. Further analysis is required to show whether
TRP generates additional expenditures by inducing switching costs and reducing patient compliance. Potential
confounding factors may limit the generalisability of our conclusions.Background
The question of what proportion of total healthcare
costs should be financed from public resources and what
proportion should be spent on pharmaceuticals is under
continuous debate in Hungary [1]. Before 2006, the pro-
portion of the total drug cost financed from public
resources was larger than the average for OECD coun-
tries. Furthermore, between 2000 and 2006, the increase
in public pharmaceutical expenditures exceeded the an-
nual rate of 17%. Therefore, the Hungarian National* Correspondence: kalo@tatk.elte.hu
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reproduction in any medium, provided the orHealth Insurance Fund (NHIF) applied a series of cost-
containment measures to limit the growth rate of
pharmaceutical spending [2,3].
One element of these measures was the extension of
the therapeutic reference pricing (TRP) system, also
known as the system of therapeutic reference classes. The
method implies that the actual reimbursement for the
drugs included in the same class (e.g. ATC class with four
or five digits) is maximised in line with the average price
of products, with the lowest daily therapeutic costs
included in that class. The payer indirectly influences the
drug price by defining the maximum reimbursement
according to the preferred price, and manufacturers can
reduce the price of non-referenced products to avoid
high copayment. The group of referenced products with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of 50% in the whole class, measured by the number
of days of treatment (DOT).
Several technical objections may be raised against the
implementation of the TRP system [4]. First, when in-
cluding drugs that contain different active ingredients in
the same reference class, decision-makers usually fail to
take into account significant differences in the indica-
tions of the drugs, despite their similar mechanisms of
action. Second, even if the indications of drugs in a TRP
group are the same, there may still be some differences
in their efficacy, tolerability and adverse event profiles in
the entire patient population or in a subgroup of
patients. Because different substances in the same class
can be metabolised in different ways, they may show dif-
ferent drug interaction profiles. In such cases, the opti-
mal therapy for a certain group of patients may differ
from the medication that is appropriate for most other
patients. TRP for inhalation drugs raises special concern
because, despite the identical route of administration,
the different characteristics of the inhalation devices
may lead to differences in efficacy (e.g. lung deposition).
Finally, the establishment of therapeutically equivalent
daily doses can be difficult in the case of TRP because
comparisons can be made only according to the princi-
ples of evidence-based medicine based on direct com-
parative studies. Instead of this, the WHO DDD
(average defined daily dose) is used as the basis for the
equivalent dose by payers. Even the WHO, however,
objects to the use of DDD in decision-making regarding
efficacy, pricing and reimbursement [5].
Although concerns have been raised about the use of
TRP from the perspective of drug innovation and indus-
trial policy, these are usually offset by financial aspects
because the widespread use of reference pricing can lead
to massive savings in the pharmaceutical budget [6] [7].
The impact of TRP is often mixed with savings from
generic reference pricing (GRP), so it is difficult to deter-
mine how much of the saving from reference pricing is
attributable to the increased utilisation of generics and
generic price erosion. In some cases, when the impact of
TRP is separated from GRP, TRP does not display clear
savings in pharmaceutical expenditures [8].
The aim of our study was to evaluate the effects of
TRP in the case of drugs used in the treatment of
asthma. High-dose Seretide Diskus and SymbicortW Tur-
buhalerW with maximum reimbursement rates of 90%
had already been reimbursed by the TRP system within
the R03AK06 ATC group. During the period of the ana-
lysis no other original or generic products were included
in this TRP group. The inclusion of the medium-dose
products in this pricing system seems to be the next
feasible step. In the high-dose class, TRP ensured an ad-
vantageous position for the Symbicort Turbuhaler onthe basis of the WHO DDD because the price of a daily
dose is 3.7% lower than the price of Seretide Diskus.
TRP for a medium dose would make the Seretide Diskus
the reference product because the price of a daily dose is
21.2% to 24.1% lower than the price of the two packaged
forms of Symbicort.
There are several differences, however, between Sere-
tide Diskus and Symbicort Turbuhaler regarding the
indications for and the effects of the drugs. Symbicort
Turbuhaler can also be used as maintenance and reliever
therapy, unlike Seretide Diskus, which is appropriate
only for maintenance therapy. This difference results
from formoterol, the beta-agonist component of Symbi-
cort. Unlike salmeterol, formoterol not only has a long-
term effect but also a rapid bronchodilating effect [9].
Formoterol reaches its effect in three to four minutes,
similarly to the widely-used reliever salbutamol [10].
Compared with salmeterol, formoterol has a possible
advantage in its dose-dependent bronchoprotective
effects on methacholine-induced bronchoconstriction
[11]. The maximum daily dose of formoterol in the
treatment of asthma is eight inhalations, or 36 mcg;
however, for temporary regiments of a few days, 12 inha-
lations, or 54 mcg, are also allowed. The same cannot be
said for salmeterol because its maximum daily dose is
100 mcg or 2x1 inhalation for all dosage forms of this
product. This is because of the narrow therapeutic win-
dow, the systemic effects that appear above the maximal
dose and the lack of further smooth muscle-relaxing
effects above the maximal dose [12,13].
Taking into account the WHO DDD, it can be expected
that the price of Symbicort Turbuhaler for patients on
chronic therapy will be lower for the high-dose form
and higher for the medium dose when compared with
Seretide Diskus. Due to the rapid bronchodilating effects
of Symbicort, the use of other relievers is expected to be
lower in patients using Symbicort Turbuhaler than in
those treated with Seretide Diskus.
Due to its wide therapeutic window and rapid reliever
effects, formoterol allows for acute needs-based adminis-
tration (see the SMART indication for Symbicort), which
may reduce the number of exacerbations if the steroid
component is administered at the appropriate time. Fur-
thermore, the narrower therapeutic window of salme-
terol could lead to a higher incidence of adverse events
in patients exceeding the upper limit of the therapeutic
window.
In our study we evaluated whether in the real world
there was a difference in the costs of maintenance medi-
cation, attack-reliever therapies, treatment of exacerba-
tions and total direct health expenditures between
patients treated with Symbicort Turbuhaler and Seretide
Diskus. We used real-world cost data from the NHIF for
analysis.
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For the selection of patients, we used real-world out-
patient care, inpatient care and drug utilisation databases
(data on prescriptions filled in pharmacies) of the NHIF.
IRB approval was not necessary for the retrospective
analysis of aggregated patient records.
We included adult patients who were born before
1990, had filled a medium- or high-dose prescription of
Symbicort (SYT) or Seretide Diskus (SED) in the first
two months of 2008, and had filled a SYT or SED pre-
scription at least twice in 2008 with 90% reimbursement
of NHIF with an asthma ICD10 code (J45, J96). We
excluded patients who filled prescriptions for both study
drugs (i.e. those who were mixing SYT and SED or those
who also used Seretide Evohaler) and those who filled
different dosage forms in 2008 (Table 1).
The National Health Insurance Fund provided us with
data on the mean annual costs for 2008 for the following
cost items by age group (18–30, 31–40, 41–50, 51–60,
61–70, >70 years), gender, maintenance drug type (SYT
or SED) and dosage form (medium or high dose):
1. units and public prices of maintenance antiasthmatic
pharmaceutical therapies (SYT or SED),
2. units and public prices of reliever medications (drugs
containing salbutamol, terbutaline or fenoterole),
3. units and public prices of medications used for
exacerbation (containing ampicillin, amoxicillin,
penicillin, tetracycline, trimetoprim and
sulfamethoxazole, cefuroxime, cefamandol, cefaclor,
cefprozil, cefotaxim, ceftazidim, ceftriaxon, cefixim,
cefoperazone, ceftibuten, azithromycin,
clarithromycin, roxithromycin, ofloxacin,
ciprofloxacin, levofloxacin, moxifloxacin, or
methylprednisolone).
4. public prices of all filled prescription drugs,
5. reimbursement for outpatient care required for
asthma (the ICD code of the disease justifying the
care being J45 or J96),
6. reimbursement for all outpatient care,
7. reimbursement for inpatient care required for
asthma (the ICD code of the disease justifying the
care being J45 or J96),
8. reimbursement for all inpatient care.Table 1 Classification of study drugs according to strength
Name Package form Numb
Symbicort Forte Turbuhaler 1 × 60 doses
Seretide Diskus 50/500 1 × 60 doses
Symbicort Turbuhaler 1 × 60 doses
Symbicort Turbuhaler 1 × 120 doses
Seretide Diskus 50/250 1 × 60 doses
DTC: daily therapeutic costs based on the WHO DDD (USD).We converted Hungarian forints into US dollars by
employing the 2009 GDP PPP exchange rate published
by the OECD (1 USD= 135 HUF).
We calculated the average daily inhalations of the
maintenance drugs by dividing the total quantity of pre-
scribed medications filled without the last prescription
over the number of days between the first and last first
prescriptions filled.
We did not receive data for the other comorbidities of
the patients and assumed that there were no differences
between the patient groups in this respect.
In the descriptive statistical analysis, we compared the
inpatient costs, the outpatient costs, the costs of the
maintenance medications, costs of the drugs used for ex-
acerbation, costs of the reliever therapies and all other
medication therapies, and the total costs in all four
groups (high-dose SYT, medium-dose SYT, high-dose
SED and medium-dose SED).
Next, we used multiple linear regressions to adjust the
data for the differences in gender and age distribution of
the patients receiving different maintenance treatments.
Because only aggregate data were available, it was not
possible to use linear regressions based on the trad-
itional least-square method. Instead, we performed a re-
gression analysis on the aggregated data using the
metareg program of the STATA10 statistical program
package [14]. This analysis can be considered as a way of
standardising the mean differences in costs for both age
and gender.
Results
We analysed the data from a total of 27,799 asthma
patients; 12,260 used Seretide Diskus, and 15,539 used
Symbicort Turbuhaler. Table 2 shows the distribution of
the study population according to age, gender and main-
tenance therapy. The proportion of the patients over
60 years of age was a few percentage points higher in all
study groups among Seretide users than among Symbi-
cort users.
Average drug use was lower in both groups than the
WHO DDD, which consists of two daily inhalations for
the medium and high doses of Seretide but two daily
inhalations for the high dose and four daily inhalations
for the medium dose of Symbicort. In the Seretideer of days of treatment Strength DTC
30 high dose 3.35
30 high dose 3.48
15 medium dose 3.57
30 medium dose 3.35
30 medium dose 2.64
Table 2 Distribution of the study population by age group, gender, maintenance therapy and strength of therapy
High dose therapy Medium dose therapy
Male Female Male Female
Age group (year) Seretide Symbicort Seretide Symbicort Seretide Symbicort Seretide Symbicort
18-30 93 (3.7%) 125 (7.6%) 100 (3.0%) 79 (3.5%) 364 (16.4%) 728 (16.5%) 321 (7.7%) 703 (9.7%)
31-40 176 (7.0%) 188 (11.4%) 195 (5.8%) 183 (8.2%) 295 (13.3%) 753 (17.1%) 355 (8.5%) 804 (11.1%)
41-50 249 (9.9%) 210 (12.8%) 424 (12.6%) 336 (15.0%) 305 (13.8%) 627 (14.2%) 556 (13.3%) 1 106 (15.3%)
51-60 654 (26.1%) 382 (23.2%) 1 008 (30.0%) 685 (30.6%) 451 (20.3%) 878 (19.9%) 1 100 (26.4%) 1 956 (27.0%)
61-70 679 (27.1%) 416 (25.3%) 842 (25.0%) 522 (23.3%) 423 (19.1%) 797 (18.1%) 954 (22.9%) 1 528 (21.1%)
71-X 654 (26.1%) 326 (19.8%) 795 (23.6%) 436 (19.5%) 380 (17.1%) 622 (14.1%) 887 (21.3%) 1 149 (15.9%)
Total 2 505 (100%) 1 647 (100%) 3 364 (100%) 2 241 (100%) 2 218 (100%) 4 405 (100%) 4 173 (100%) 7 246 (100%)
Numbers are patient numbers (% column).
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tions for both doses. Symbicort users showed a very
similar pattern; the patients used an average of 1.28 to
1.97 daily inhalations of the high-dose product and 1.74
to 2.49 inhalations of the medium-dose product. The lat-
ter showed the largest difference compared with the
daily doses established by the WHO. In addition, it was
observed that women used a significantly lower dose of
Symbicort than men, both for high and medium doses
(Table 3).
Table 4 summarises the results of the cost analysis.
There were statistically significant differences for all
medication-related cost items in the groups of patients
using high-dose medications. The costs of the reliever
medications (mean difference of 3.7 USD), the medica-
tions for exacerbation (mean difference of 15.9 USD)
and the total medications (mean difference of 125.8
USD) were significantly lower in Symbicort users than in
Seretide users. The cost of maintenance therapy (mean
difference of 53.3 USD) for asthma was significantly
lower for Seretide users. The costs of outpatient and in-
patient care were similar between the groups.
Although the daily therapeutic costs calculated from
the WHO DDD should be much lower for Seretide
users, we did not find a difference in the actual costs ofTable 3 Average daily inhalation of Symbicort Turbuhaler and
High dose therapy
Male Female
Age (years) Seretide Symbicort Seretide Symbi
18-30 1.38 1.28 1.36 1.1
31-40 1.34 1.97 1.28 1.4
41-50 1.61 1.62 1.34 1.4
51-60 1.46 1.66 1.37 1.5
61-70 1.51 1.87 1.47 1.6
>70 1.50 1.67 1.42 1.7the maintenance therapy in patients using medium-dose
medications. The cost of reliever medications in Symbi-
cort users was significantly lower, by 2.2 USD, than in
Seretide users. No differences were found in the costs of
the medications for exacerbation or in total drug costs.
The outpatient and inpatient care costs for asthma
were significantly lower in the adjusted analysis in the
Seretide group. No significant differences were found be-
tween the two groups in terms of total medical costs.
Discussion
In our study we evaluated whether real-world savings
could be achieved by the National Health Insurance
Fund with the current practice of therapeutic reference
pricing in the R03AK06 ATC group and, if so, whether
the therapeutic referencing methodology was appropri-
ate. In our case we did not need to apply specific meth-
odological techniques to separate the impact of TRP
from GRP, as at the time of our analysis the R03AK06
ATC group did not include any generic products.
In the groups studied, patients used smaller doses of the
drugs than recommended by the WHO DDD. Differences
between the WHO DDD and prescribed daily doses were
previously reported in several therapeutic areas [15,16].
Because the basis for therapeutic referencing is the dailySeretide Diskus in patients with asthma
Medium dose therapy
Male Female
cort Seretide Symbicort Seretide Symbicort
9 1.30 1.90 1.95 1.74
7 1.36 1.97 1.32 1.78
8 1.33 2.07 1.36 2.03
6 1.39 2.40 1.33 2.22
7 1.44 2.38 1.42 2.27
3 1.48 2.49 1.43 2.31





























Symbicort 3 888 851.7 17.8 65.9 2140.2 42.7 220.1 59.2 760.2 3120.6
Seretide 5 869 796.9 21.3 77.9 2540.3 43.1 228.6 75.2 786.6 3555.6
raw difference
(Sym vs Ser)
54.8 −3.6 −12.0 −400.1 −0.4 −8,5 −16.0 −26.4 −435.0
adjusted} difference 53.3 −3,7 −15.9 −125.8 −0.5 −9.2 −14.1 −11.4 −230.9
95% CI of the
adjusted difference
25.1; 81.6 −5.3; -2.0 −23.3; -8.5 −242.3; -9.2 −3.0; 1.9 −29.6; 11.3 −33.6; 5.4 −140.9; 118.1−628.3; 166.5
p-value 0.001 <10-3 <10-3 0.04 0.7 0.4 0.1 0.9 0.2
Medium
dose
Symbicort 11 651 575.8 11.6 43.3 1563.0 40.2 208.2 43.1 510.0 2281.2
Seretide 6 391 575.3 13.5 40.5 1590.5 38.9 211.2 30.0 494.4 2296.1
raw difference
(Sym vs Ser)
0.6 −1.9 2.7 −27.5 1.3 −3.0 13.1 15.6 −14.9
adjusted} difference 0.6 −2.2 3.4 9.0 1.7 3.8 14.2 34.9 93.1
95% CI of the
adjusted difference
−20.0; 21.2 −4.0; -0.5 −0.8; 7.6 −68.7; 86.6 0.2; 3.14 −12.3; 19.9 3.9; 24.4 −18.6; 88.3 −87.9; 274.15
p-value 0.96 0.02 0.1 0.8 0.03 0.6 0.01 0.2 0.3
CI: confidence interval.
* ICD code of the diagnosis justifying care is J45 or J96.
† the ICD code on which the main diagnosis is based or that for the main diagnosis justifying the care is J45 or J96.
{ total costs of drugs, both outpatient and inpatient care.
} adjusted for age and gender.
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provides evidence for the limitations of this method in
asthma. No relationship was found between the daily
therapeutic costs calculated by means of the NHIF meth-
odology and the real-world costs of actual drug use.
Therefore, in our presented case the expected lower daily
therapeutic costs did not exist in practice.
Our analysis also showed that therapeutic referencing
based solely on the daily therapeutic costs in the
R03AK06 group did not lead to a reduction of expend-
iture for the payer. TRP might even generate additional
expenditures, as in addition to the costs calculated in
this analysis, costs related to a switch to another treat-
ment should also be taken into account. When patients
change inhalation devices, they need to learn how to use
the new device. Moreover, switching to a new inhalation
device may reduce compliance due to the individual pre-
ferences of the patients, which may eventually lead to
decreased effectiveness [17,18].
In interpreting the results, it should be taken into ac-
count that Seretide doses can only be increased by
switching from the medium dose to the high dose; con-
sequently, these cases were excluded from this study.
The doses for Symbicort, on the other hand, can beadjusted in a different way because a daily dose of 2x1
inhalations can be increased to 2x2 inhalations. There-
fore, an appropriate comparison for some of the patients
using a medium dose of Symbicort would have been
high-dose Seretide, which is also supported by the fact
that daily inhalations of the medium dose of Symbicort
were relatively high compared with the medium dose of
Seretide. The higher daily inhalations of Symbicort may
also be explained by the Symbicort SMARTW indication.
Although an analysis that took into account this dose
increase could have been performed on individual
patient data, we only had access to aggregated admin-
istrative financing data in this study.
Nevertheless, although this analysis followed a conser-
vative approach with regard to Symbicort, NHIF still
could not expect any real-world savings by referencing
the WHO DDD.
This study also shows that administrative financial
data support the clinical data, which suggest a decreased
need for relievers and exacerbation treatments if patients
are treated with Symbicort. This proves that differences
in the indications cannot be disregarded during the
process of referencing and that different indications
should not be treated in the same way.
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sion criteria guarantee that SYT and SED were pre-
scribed for patients with asthma indication and not
COPD, coding errors could not be excluded due to the
retrospective nature of our analysis.
Medications for exacerbations could also be prescribed
for non-asthma-related events. Similarly, outpatient and
inpatient episodes could also be related to other comor-
bidities, so conclusions related to these outcomes have
limited generalisability.
Confounding factors may bias our results. Theoretic-
ally, the different characteristics between the two study
groups may partially explain the differences in costs.
The effects of confounding could have been controlled
by a multiple regression analysis. For such analyses,
however, individual patient data would be required.
According to the NHIF, however, such data could not be
released for research purposes, not even in an anonym-
ous form. Nevertheless, we used an adjustment method
based on the aggregated data to control for age and
gender.Conclusion
Cost-containment initiatives by payers may influence
clinical decisions. TRP for inhalation asthma drugs raises
special concern, because of differences in the therapeutic
profile of pharmaceuticals and the lack of proven finan-
cial benefits after exclusion of the effect of generic price
erosion. Our findings indicate that the presented TRP
approach of asthma medications based on the daily
therapeutic costs according to the WHO DDD does not
result in reduced public healthcare spending in Hungary.
Further analysis is required to show whether TRP gen-
erates additional expenditures by inducing switching
costs and reducing patient compliance. Potential con-
founding factors may limit the generalisability of our
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